Prosecution Insights
Prosecution Insights
8 pending office actions • 6 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| NOTTINGHAM, KYLE GREGORY | 1 | 59.3% | +34.9% |
| LIPPERT, JOHN WILLIAM | 1 | 56.6% | +41.3% |
| YU, DELPHINUS DOU YI | 1 | 50.0% | +0.0% |
| HSU, GRACE CHING | 1 | 76.6% | +27.5% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 39.3% | +70.3% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.6% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 46d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 46d overdue |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 8d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 57d |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | OUSPENSKI, ILIA I | 77d |
| 18767400 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | NOTTINGHAM, KYLE GREGORY | — |
| 18682398 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | LIPPERT, JOHN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1621 | 1 |
| 1636 | 1 |
| 1627 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767400 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | NOTTINGHAM, KYLE GREGORY | 1621 | §112DP | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18682398 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | LIPPERT, JOHN WILLIAM | — | §103 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 1636 | §101§102§112Other | Non-Final OA | 56d | Pending | May 24, 2023 |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 1627 | §102§112Other | Non-Final OA | 46d overdue | Pending | Apr 18, 2023 |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102 | Non-Final OA | 34d | Pending | Sep 13, 2022 |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | OUSPENSKI, ILIA I | 1644 | §102§112DPOther | Non-Final OA | 77d | Pending | Aug 11, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 1635 | DP | Final Rejection | 8d overdue | Pending | Nov 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial